Search Results for ""drugs for""
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for "drugs for". Results 2261 to 2270 of 2582 total matches.
High Altitude Sickness
The Medical Letter on Drugs and Therapeutics • Sep 04, 1992 (Issue 878)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Rapid exposure to altitudes more than 8,000 feet above sea level can cause serious medical problems. Since the last Medical Letter article on this subject (Vol. 30, page 89, 1988), some new information on prevention and treatment of these disorders has been reported.
Radiofrequency Catheter Ablation for Treatment of Cardiac Arrhythmias
The Medical Letter on Drugs and Therapeutics • Apr 26, 1996 (Issue 973)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
In recent years, selective destruction of cardiac tissue by radiofrequency energy has become a routine procedure for treatment of some types of cardiac arrhythmias, particularly supraventricular tachycardias (MM Scheinman, Pacing Clin Electrophysiol, 18:1474, 1995).
Insulin Glargine (Lantus), A New Long-acting Insulin
The Medical Letter on Drugs and Therapeutics • Aug 06, 2001 (Issue 1110)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Insulin Glargine (Lantus) is a new long-acting human insulin analog approved by the FDA for treatment of both type 1 and type 2 diabetes. Synthesized by recombinant DNA technology, it differs from human insulin at position 21 in the A-chain where asparagine is replaced by glycine and at the C-terminus of the B-chain where two arginines are added.
Twinrix: A Combination Hepatitis A and B Vaccine
The Medical Letter on Drugs and Therapeutics • Aug 06, 2001 (Issue 1110)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
A vaccine to prevent both Hepatitis A and Hepatitis B (Twinrix), previously licensed in Canada and Europe, is now available in the US for adults.
Darbepoetin (Aranesp) - A long-acting Erythropoietin
The Medical Letter on Drugs and Therapeutics • Dec 10, 2001 (Issue 1120)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Darbepoetin alfa (Aranesp) has been approved by the FDA for treatment of anemia caused by chronic renal disease and will probably also be approved for use in patients with cancer..
Antiviral KLEENEX
The Medical Letter on Drugs and Therapeutics • Jan 03, 2005 (Issue 1199)
The Medical Letter
®
On Drugs and Therapeutics
3
FORWARDING OR COPYING IS A VIOLATION OF U.S ...
The first commercially available virucidal tissue, KLEENEX Anti-Viral Tissue (Kimberly-Clark), was recently introduced and is being heavily promoted to the general public. Patients may ask healthcare providers about the usefulness of these products. Theoretically, virucidal tissues could interrupt transmission of viral infections by blocking hand contamination and/or small particle aerosols from nose-blowing, sneezing and coughing.
Virtual Colonoscopy
The Medical Letter on Drugs and Therapeutics • Feb 14, 2005 (Issue 1202)
Letter
®
On Drugs and Therapeutics
IN THIS ISSUE
Volume 47 (Issue 1202)
February 14, 2005 ...
Currently available techniques for colorectal cancer screening include fecal occult-blood testing, flexible sigmoidoscopy, double contrast barium enema (DCBE) and traditional optical colonoscopy. Optical colonoscopy requires bowel cleansing and sedation, and involves some risk, but is generally accepted as the best available method for detection of lesions and offers the advantage that polyps can be removed when they are identified. A less invasive screening tool, computed tomography (CT) colonography, also known as virtual colonoscopy (VC), offers an additional option.
Ceftaroline Fosamil (Teflaro) - A New IV Cephalosporin
The Medical Letter on Drugs and Therapeutics • Jan 24, 2011 (Issue 1356)
The Medical Letter®
On Drugs and Therapeutics
Volume 53 (Issues 1356)
January 24, 2011 ...
The FDA has approved ceftaroline fosamil (Teflaro –
Forest), an intravenous (IV) cephalosporin, for treatment
of acute bacterial skin and skin structure infections,
including those caused by methicillin-resistant
Staphylococcus aureus (MRSA), and for treatment of
community-acquired bacterial pneumonia in adults. It
is the first beta-lactam antibiotic approved for treatment
of MRSA.
Shingrix - An Adjuvanted, Recombinant Herpes Zoster Vaccine
The Medical Letter on Drugs and Therapeutics • Dec 04, 2017 (Issue 1535)
reserved. ©2017. www.fdbhealth.com/policies/drug-pricing-policy.
196
The Medical Letter ® Vol. 59 (1535 ...
The FDA has approved an adjuvanted, recombinant
varicella zoster virus (VZV) vaccine (Shingrix – GSK)
for prevention of herpes zoster (shingles) in adults ≥50
years old. Shingrix is the second herpes zoster vaccine
to be approved in the US; Zostavax, a live-attenuated
VZV vaccine approved for the same indication, has been
available since 2006.
An EUA for Bamlanivimab and Etesevimab for COVID-19
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021 (Issue 1621)
disease that
requires daily drug treatment
BMI = body mass index; COPD = chronic obstructive pulmonary ...
The FDA has issued an Emergency Use Authorization
(EUA) for Lilly's investigational monoclonal antibodies
bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016)
to be administered together for treatment of
mild to moderate COVID-19 in patients ≥12 years old
who weigh ≥40 kg and are at high risk of progressing
to severe disease and/or hospitalization (see Table 1).
Bamlanivimab received an EUA for use as monotherapy
in such patients in November 2020. Regeneron's
investigational monoclonal antibodies casirivimab
(REGN10933) and imdevimab (REGN10987) are also
authorized for use...